Key result
Myocardial fibrosis fails to alter 12-month circulating microRNA kinetics in dilated cardiomyopathy.
Why the study?
The kinetics of fibrosis-linked microRNAs and their relationship with extracellular matrix fibrosis in dilated cardiomyopathy have not been explored.
Do circulating fibrosis-linked microRNAs differentiate between dilated cardiomyopathy patients with and without extracellular matrix fibrosis over 12 months?
Observational (n=70)
Do circulating fibrosis-linked microRNAs differentiate between dilated cardiomyopathy patients with and without extracellular matrix fibrosis over 12 months?
Circulating fibrosis-linked microRNAs measured over 12 months do not reliably differentiate between dilated cardiomyopathy patients with and without extracellular matrix fibrosis.
Answers are grounded in this paper and cite their sources.
MicroRNA kinetics should not guide fibrosis assessment in DCM; leaves open their biomarker utility pending larger prospective studies.
Introduction A single measurement of any biomarker may not reflect its full biological meaning. The kinetics of fibrosis-linked microRNAs and their relationship with extracellular matrix (ECM) fibrosis in dilated cardiomyopathy (DCM) have not been explored. Material and methods We evaluated 70 consecutive DCM patients (48 ±12.1 years, left ventricular ejection fraction 24.4 ±7.4%). All patients underwent right ventricular endomyocardial biopsy in order to quantify ECM fibrosis and measure collagen volume fraction (CVF). Circulating microRNAs (miR-21-5p, miR-29b, miR-30c-5p, and miR-133a-3p) were measured with quantitative polymerase chain reaction (PCR) at baseline and at 3 and 12 months. Results Based on the biopsy results, two groups of patients were identified: with (n = 24, 34.3%) and without (n = 46, 65.7%) ECM fibrosis. Except for a single measurement of miR-29b at 3 months (DCM with fibrosis: 6.03 ±0.72 vs. DCM without fibrosis: 6.4 ±0.75 Cq; p < 0.05), baseline, 3- and 12-month kinetics of microRNAs did not differ between the two groups. Moreover, 12-month microRNA kinetics did not differ in patients with new-onset DCM (duration < 6 months; n = 35) and chronic DCM (> 6 months; n = 35). Only miR-29 at 3 months correlated with CVF (r = –0.31; p < 0.05), whereas other microRNAs did not correlate with CVF either at 3 or at 12 months. Conclusions Regardless of ECM fibrosis status or duration of the disease, 12-month patterns of circulating microRNAs are similar in DCM. Correlations between microRNAs, measured at 3 and 12 months, are lower than expected. In this study, regardless of the time point, circulating microRNAs were not able to differentiate between DCM patients with versus without fibrosis.
No takes yet. Share an insight, caveat, or question.
Rubiś et al. (2019) conducted an observational in Dilated cardiomyopathy (n=70). Extracellular matrix (ECM) fibrosis vs. No ECM fibrosis was evaluated on Kinetics of circulating microRNAs (miR-21-5p, miR-29b, miR-30c-5p, and miR-133a-3p) at baseline, 3, and 12 months. Extracellular matrix fibrosis did not alter the 12-month kinetics of circulating microRNAs in dilated cardiomyopathy, except for miR-29b at 3 months (6.03 vs 6.4 ΔCq; p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: